Skip to main content

Table 2 Collection rate of EQ-5D and claims data

From: Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

  QOL population Cost population
  Taxane S-1 Taxane S-1
  N = 175 N = 208 N = 70 N = 76
Baseline/Month 1 175/175 (100) 208/208 (100) 54 66
Month 3 151/171 (88.3) 168/201 (83.6) 70 70
Month 6 138/168 (82.1) 146/190 (76.8) 66 66
Month 12 107/149 (71.8) 132/170 (77.6) 49 56
Month 18 75/126 (59.5) 107/158 (67.7) 41 45
Month 24 68/117 (58.1) 93/137 (67.9) 38 45
Month 30 51/101 (50.5) 68/110 (61.8) 33 35
Month 36 45/90 (50.0) 47/84 (56.0) 32 27
Month 42 27/61 (44.3) 31/61 (50.8) 29 14
Month 48 18/39 (46.2) 21/37 (56.8) 18 15